The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

Launched by UNIVERSITY OF CHICAGO · Oct 31, 2018

Keywords

ClinConnect Summary

The ImPreSS Trial is a study looking at how genetic information can help doctors choose the best medications for patients undergoing elective surgeries at The University of Chicago. The trial involves adults aged 18 and older who are scheduled for these surgeries. Before the surgery, participants will provide a blood sample to test for specific genetic markers that can influence how they respond to certain drugs. This information will then be shared with their doctors through a secure online system called the Genomic Prescribing System (GPS), which aims to improve medication safety and effectiveness.

Participants will first take part in a six-month period where about 100 patients' genetic results will be made available to their healthcare providers. After this, patients will be randomly assigned to one of two groups: one group will have access to their genetic information when deciding on medications, while the other group will follow the current standard practices without this information. This trial is open to adults who are eligible for elective surgery, but those with specific conditions, like active leukemia or those considering organ transplants, cannot participate. Overall, the trial aims to enhance decision-making for medication during surgery using personalized genetic insights.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients who have planned elective surgical procedures at the University of Chicago
• • Must be aged 18 years or older
• Exclusion Criteria:
• • Patients who have undergone, or are being actively considered for, liver or kidney transplantation
• • Patients with known active or prior leukemia.
• • Inability to understand and give informed consent to participate.